Patents Issued in December 19, 2017
  • Patent number: 9845457
    Abstract: The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: December 19, 2017
    Assignee: Cedars-Sinai Medical Center
    Inventors: Eduardo Marbán, Tao-Sheng Li
  • Patent number: 9845458
    Abstract: Disclosed is a cell mass containing an adipose-tissue-derived multipotent progenitor cell. Also disclosed is a method for producing an adipose-tissue-derived multipotent progenitor cell from an adipose tissue, which comprises the steps of: (a) removing erythrocytes from an adipose-tissue-derived cell mass to produce a preadipose-tissue-derived multipotent progenitor cell mass; and (b) removing cells other than the adipose-tissue-derived multipotent progenitor cell from the preadipose-tissue-derived multipotent progenitor cell mass to produce the desired adipose-tissue-derived multipotent progenitor cell. Further disclosed is an adipose-tissue-derived multipotent progenitor cell produced by the method.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: December 19, 2017
    Inventors: Akifumi Matsuyama, Hiroshi Komoda, Hanayuki Ohkura, Yoshiki Sawa
  • Patent number: 9845459
    Abstract: The present invention relates to a method of obtaining high purity stem cells from tissue, comprising: providing an impurity-containing cell mass obtained from a tissue; providing a filter device which comprises a cylinder structure, wherein the cylinder structure comprise an inlet and an outlet below and a content configured inside the cylinder structure between the inlet and the outlet; culturing the impurity-free cell mass on a polymeric film, wherein target stem cells of the impurity-free cell mass conjugate into a spheroid cell population; collecting the spheroid cell population from the polymeric film to obtain high purity target stem cells. According to the method of the present invention, stem cells can be rapidly and easily obtained from tissue. Only a small amount of tissue sample is required and the stem cells obtained can be readily used in clinical applications such as autotransplantation without the requirement of in vitro amplification.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 19, 2017
    Assignee: National Taiwan University
    Inventors: Shan-Hui Hsu, Guo-Shiang Huang, Niann-Tzyy Dai, Lien-Guo Dai
  • Patent number: 9845460
    Abstract: The present invention is provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3? (GSK-3B) enzyme activity.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: December 19, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Janet Davis, Jiajian Liu
  • Patent number: 9845461
    Abstract: A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: December 19, 2017
    Assignee: CLS Therapeutics Limited
    Inventors: Dmitry Dmitrievich Genkin, Viktor Veniaminovich Tets, Georgy Viktorovich Tets
  • Patent number: 9845462
    Abstract: The present invention provides methods for the cultivation of the Methylobacterium genus of bacteria. In particular the method provides methods for the efficient and inexpensive cultivation of these bacteria. Additionally, the invention provides methods for the utilization of these bacterial cultures to improve plant agriculture.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: December 19, 2017
    Assignee: NEWLEAF SYMBIOTICS, INC.
    Inventor: Gregg Bogosian
  • Patent number: 9845463
    Abstract: Provided are methods and columns employing a solid support comprising silica and silicon carbide for the isolation and purification of nucleic acids, and in particular, the isolation and purification of both high and low molecular weight RNA.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: December 19, 2017
    Assignee: NORGEN BIOTEK CORP.
    Inventor: Yousef Haj-Ahmad
  • Patent number: 9845464
    Abstract: Methods for display of recombinant proteins or protein libraries on the surface of lower eukaryotes such as yeast and filamentous fungi are described. The methods are useful for screening libraries of recombinant proteins in lower eukaryotes to identify particular proteins with desired properties from the array of proteins in the libraries. The methods are particularly useful for constructing and screening antibody libraries in lower eukaryotes.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: December 19, 2017
    Assignee: GlycoFi, Inc.
    Inventors: Dongxing Zha, Stefan Wildt
  • Patent number: 9845465
    Abstract: The present application discloses roles for miR-93 in treating hypoxia and ischemia. Endothelial cells (HUVEC) and myocytes (C2C12) expressed miR-93 and up-regulated miR-93 in response to hypoxia and serum starvation. Over-expression of miR-93 in HUVECs promoted cell proliferation, prevented hypoxia-induced apoptosis, and enhanced endothelial cell tube formation. miR-93 knockdown in HUVECs resulted in increased hypoxia-induced apoptosis and decreased tube formation. Over-expression or knockdown of miR-93 in myocytes resulted in reduced or increased hypoxia-induced apoptosis, respectively. Down-regulation of miR-93 in C57BL/6 mice with antagomiR resulted in attenuated perfusion recovery (% non-ischemic leg at day-21: Scramble 85.22.9 vs. AntagomiR-93 67.96). Over-expression of miR-93 in BALB/C mice improved perfusion recovery (% non-ischemic leg at day 21: PremiR-93 757.5 vs. Scramble 59.62.5).
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: December 19, 2017
    Assignee: University of Virginia Patent Foundation
    Inventors: Brian H. Annex, Charles R. Farber, Surovi Hazarika
  • Patent number: 9845466
    Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 19, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
  • Patent number: 9845467
    Abstract: The present invention provides compounds and methods for modulating target nucleic acids found in organelles or sub-organelles of cells. The invention includes, but is not limited to compounds and methods that modulate target nucleic acids in a sub-nuclear organelle, such as the nucleolus and/or a cajal body. In certain embodiments, the cell is in an animal.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 19, 2017
    Assignees: Ionis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: Xue-hai Liang, Stanley T. Crooke, C. Frank Bennett, David L. Spector
  • Patent number: 9845468
    Abstract: The present invention provides compounds and methods for modulating target nucleic acids found in organelles or sub-organelles of cells. The invention includes, but is not limited to compounds and methods that modulate target nucleic acids in a sub-nuclear organelle, such as the nucleolus and/or a cajal body. In certain embodiments, the cell is in an animal.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 19, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Xue-hai Liang, Stanley T. Crooke
  • Patent number: 9845469
    Abstract: Various aspects of the present invention are directed to compounds targeted to various regions of the survival motor neuron 2 (SMN2) gene. Such compounds may be used to increase incorporation of exon 7 in processed transcripts of SMN2. Such compounds may therefore be useful in increasing the amount of full-length SMN protein produced by the SMN2 gene. As such, these compounds may provide a therapeutic approach for treatment of spinal muscular atrophy (SMA).
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: December 19, 2017
    Assignee: Ohio State Innovation Foundation
    Inventors: Arthur Burghes, Vicki McGovern, Thomas Prior
  • Patent number: 9845470
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 19, 2017
    Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 9845471
    Abstract: The present disclosure provides compositions and methods for treating or reducing the risk of pancreatic cancer by administering compounds capable of inhibiting the expression or activity of RUNX3.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: December 19, 2017
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Sunil R. Hingorani
  • Patent number: 9845472
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: December 19, 2017
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • Patent number: 9845473
    Abstract: The invention discloses a method for improving immunity in shrimps, by administering a double-stranded RNA specific to tyrosine hydroxylase to a shrimp body to improve immunity of the shrimp body, wherein the double-stranded RNA is administered to the shrimp body by injection into the ventral sinus of the cephalothorax of the shrimp body.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 19, 2017
    Assignee: NATIONAL PINGTUNG UNIVERSITY OF SCIENCE & TECHNOLO
    Inventors: Wen-Teng Cheng, Chin-Chyuan Chang, Wan-Lin Tsai
  • Patent number: 9845474
    Abstract: The present disclosure relates to genetically engineered methanotrophic bacteria with the capability of growing on a multi-carbon substrate as a primary or sole carbon source and methods for growing methanotrophic bacteria on a multi-carbon substrate.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: December 19, 2017
    Assignee: Calysta, Inc.
    Inventors: Joshua A. Silverman, Effendi Leonard, Renee M. Saville
  • Patent number: 9845475
    Abstract: An expression vector for expressing a target polypeptide in a prokaryotic cell is provided. The vector comprises a promoter operably linked to a polynucleotide encoding the target polypeptide operably linked to a eukaryotic secretion leader sequence, the eukaryotic secretion leader sequence encoding a signal peptide sequence selected from the group consisting of: a) MLKRSSWLATLGLLTVASVSTIVYA; b) MKKATFITCLLAVLLVSNPIWNA; c) MKVSAAALAVILIATALCAPASA; d) MKVSTAFLCLLLTVSAFSAQVLA; and e) MKCLLLALGLALACAAQA. Processes for expressing polypeptides and prokaryotic microorganisms comprising such vectors are also provided.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: December 19, 2017
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventors: Bhupendra Vallabh Kara, Christopher David John Lennon
  • Patent number: 9845476
    Abstract: The present invention provides improved polysaccharides (e.g., gellan and diutan) produced by mutant gene R, M or N Sphingomonas strains containing at least one genetic modification that favors slime-forming polysaccharide production. Methods of making the mutant Sphingomonas strains and the culture broth containing such mutant Sphingomonas strains are also provided.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: December 19, 2017
    Assignee: CP Kelco U.S., Inc.
    Inventors: Nancy E. Harding, Yamini N. Patel, Russell J. Coleman
  • Patent number: 9845477
    Abstract: The invention provides DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. Transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides are also provided, as are methods of their use.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: December 19, 2017
    Assignee: Monsanto Technology LLC
    Inventors: Stanislaw Flasinski, Barrett C. Foat, Mohammed Oufattole, Randall W. Shultz, Xiaoping Wei, Wei Wu, Shiaw-Pyng Yang
  • Patent number: 9845478
    Abstract: The invention provides promoter sequences that regulate specific expression of operably linked sequences in developing xylem cells and/or in developing xylem tissue. The developing xylem-specific sequences are exemplified by the DX5, DX8, DX11, and DX15 promoters, portions thereof, and homologs thereof. The invention further provides expression vectors, cells, tissues and plants that contain the invention's sequences. The compositions of the invention and methods of using them are useful in, for example, improving the quantity (biomass) and/or the quality (wood density, lignin content, sugar content etc.) of expressed biomass feedstock products that may be used for bioenergy, biorefinary, and generating wood products such as pulp, paper, and solid wood.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: December 19, 2017
    Assignee: Board of Trustees of Michigan State University
    Inventors: Kyung-Hwan Han, Jae-Heung Ko
  • Patent number: 9845479
    Abstract: The present invention relates to genetic control of infestation by insect pest species, particularly prevention and/or control of pest infestation of plants, using interfering ribonucleic acid (RNA) molecules. The invention provides transgenic plants that (i) express or are capable of expressing interfering RNAs of the invention and (ii) are resistant to infestation by insect pest species.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: December 19, 2017
    Assignee: Devgen NV
    Inventors: Myriam Beghyn, Thierry Andre Olivier Eddy Bogaert, Pascale Feldmann, Romaan Raemaekers
  • Patent number: 9845480
    Abstract: The present invention includes methods for effecting phenotype conversion in a cell by transfecting the cell with phenotype-converting nucleic acid. Expression of the nucleic acids results in a phenotype conversion in the transfected cell. Preferably the phenotype-converting nucleic acid is a transcriptome, and more preferably an mRNA transcriptome.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: December 19, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: James Eberwine, Jai-Yoon Sul, Tae Kyung Kim, Vickas Patel
  • Patent number: 9845481
    Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: December 19, 2017
    Assignee: Duke University
    Inventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
  • Patent number: 9845482
    Abstract: Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: December 19, 2017
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Jonathan L. Tilly, David A. Sinclair
  • Patent number: 9845483
    Abstract: The invention relates to an alcoholic fermentation process in the presence of one or more high alcohol tolerant yeast and one or more maltotriose positive yeast. The process of the present invention can be a fermentation process for the production of ethanol, for the production of beer, for the production of wine and the like. in a preferred embodiment, the present invention relates to a process for the production of ethanol in the presence of distiller's yeast and baker's yeast.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: December 19, 2017
    Assignee: CARGILL, INCORPORATED
    Inventors: Jean-Claude Marie Pierre De Troostembergh, Bernhard Horbach, Michael Josef Christian Kruse, Nicolas Andre Albert Meurens
  • Patent number: 9845484
    Abstract: Provided herein are recombinant yeast cells having an active 3-Hydroxypropionic Acid (3-HP) pathway and further comprising a heterologous polynucleotide encoding an aspartate 1-decarboxylase (ADC) of the Class Insecta, Bivalvia, Branchioporia, Gastropoda, or Leptocardii. Also described are methods of using the recombinant yeast cells to produce 3-HP and acrylic acid.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: December 19, 2017
    Assignee: NOVOZYMES A/S
    Inventors: Michelle Barnhart, Ana Negrete-Raymond, Janice Frias, Gui Barbier, Michael Catlett
  • Patent number: 9845485
    Abstract: Provided are microalgae of the genus Euglena that fall under Euglena gracilis strain EOD-1 (Accession No. FERM BP-11530) or its mutant strain and that are capable of producing at least polysaccharides. Further provided is a method for producing polysaccharides including: culturing microalgae of the genus Euglena that fall under Euglena gracilis strain EOD-1 (Accession No. FERM BP-11530) or its mutant strain and that are capable of producing at least polysaccharides as polysaccharide-producing organisms to produce the polysaccharides. Further provided is a method for producing an organic compound including: culturing microalgae of the genus Euglena that fall under Euglena gracilis strain EOD-1 (Accession No. FERM BP-11530) or its mutant strain and that are capable of producing at least polysaccharides to produce at least one organic compound selected from the group consisting of polysaccharides, lipids, vitamin C, vitamin E, pigments, and proteins.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: December 19, 2017
    Assignee: Kobelco Eco-Solutions Co., Ltd.
    Inventors: Makoto Watanabe, Mikihide Demura, Masanobu Kawachi, Natsuki Sato, Akira Akashi, Jun Takezaki, Takeshi Hamada, Madoka Takahashi, Kenji Ohiraki
  • Patent number: 9845486
    Abstract: The present invention provides novel enrichment, testing and detection methods for detection of pathogens or other microbes in a food, water, wastewater, industrial, pharmaceutical, botanical, environmental samples and other types of samples analyzed by enrichment-detection methods. In preferred aspects, a sample is obtained at a first location and is diluted (e.g., in the case of a solid or semi-solid sample or liquid) at the first location at a ratio of about 1:0 (wt./vol.) to 1:2 (wt./vol.), or greater, preferably at a ratio of about 1:0.1 (wt./vol.) or greater, or more preferably, at a ratio of about 1:2 (wt./vol.) or greater. The diluted sample is incubated at an optimal temperature in an incubator and either tested locally, or sent in a shipping incubator to a second location that is a remote test location. The incubated sample is received and tested at the second location by assaying the sample, or a portion thereof, with an assay suitable to detect the pathogen or other microbe.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: December 19, 2017
    Assignee: Institute for Environmental Health, Inc.
    Inventor: Mansour Samadpour
  • Patent number: 9845487
    Abstract: The invention deals with chromogenic media which are suitable for the selective growth and identification of one or more species of yeast. The subject of the invention is the method that enables us to identify and determine the cell count of Brettanomyces/Dekkera and Zygosaccharomyces yeasts. Besides, the subjects of invention are also the use of the method in wine and/or food industry and the stocks for conducting the experiment.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: December 19, 2017
    Assignees: Szegedi Tudományegyetem, SOLVO Biotechnológiai ZRt.
    Inventors: Csaba Vágvölgyi, Ilona Pfeiffer, János Márky-Zay
  • Patent number: 9845488
    Abstract: A method for isolating biomolecules from a fixed biological specimen embedded in paraffin, comprises the steps of bringing the specimen into contact a) with a solvent non-miscible with water and dissolving the paraffin in this solvent such as to form a liquid organic phase, and b) with an aqueous solution of at least one lysis substance and/or with water and at least one lysis substance such as to form an aqueous phase; isolation of the biomolecules from the aqueous phase. The invention further relates to a corresponding kit as well as to the use of such a kit for isolating biomolecules.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: December 19, 2017
    Assignee: Axagarius GmbH & Co. KG
    Inventors: Christoph Kirsch, Claudia Beyard, Markus Meusel, Klaus Moeller
  • Patent number: 9845489
    Abstract: Compositions and methods are disclosed for substantially liquid, gel, suspension, slurry, semisolid and/or colloid storage of biological samples following admixture with the herein disclosed storage composition, permitting substantial recovery of biological activity following storage without refrigeration. In certain embodiments, unfractionated saliva samples may be stored without refrigeration for weeks, months or years in a form that permits recovery of intact DNA following the storage period.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: December 19, 2017
    Assignee: BIOMATRICA, INC.
    Inventors: Scott E. Whitney, Senait Ghirmai, Rolf Muller
  • Patent number: 9845490
    Abstract: The presently claimed invention provides for novel methods and kits for analyzing a collection of target sequences in a nucleic acid sample. A sample is amplified under conditions that enrich for a subset of fragments that includes a collection of target sequences. The invention further provides for analysis of the above sample by hybridization to an array, which may be specifically designed to interrogate the collection of target sequences for particular characteristics, such as, for example, the presence or absence of one or more polymorphisms.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: December 19, 2017
    Assignee: Affymetrix, Inc.
    Inventors: Hajime Matsuzaki, Xing Su, Sean Walsh, Giulia Kennedy, Rui Mei
  • Patent number: 9845491
    Abstract: Provided herein is technology relating to isolating nucleic acids. In particular, the technology relates to methods and kits for extracting nucleic acids from problematic samples such as stool.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: December 19, 2017
    Assignee: Exact Sciences Corporation
    Inventors: Janelle J. Bruinsma, Michael J. Domanico, Graham P. Lidgard, Hongzhi Zou, William G. Weisburg, Hemanth D. Shenoi, James P. Light, II, Keith Kopitzke, John Zeis
  • Patent number: 9845492
    Abstract: The present invention relates to the detection of a target nucleic acid sequence in a real-time manner using a target signal generating primer (TSG primer) having dual interactive labels. The present invention allows for both target amplification and signal amplification by introducing dual interactive labels into a primer used in PCR reactions, ensuring real-time target detection by PCR reactions without the use of complicated oligonucleotides. The present invention could be free from the troublesome matters and shortcomings associated with conventional real-time PCR methods. The present invention allows for successful real-time target detection by using only a labeled primer. Also, the present invention can obtain strong signals indicative of the presence of target nucleic acid sequences in both a liquid phase and solid phase.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: December 19, 2017
    Assignee: SEEGENE, INC.
    Inventors: Jong Yoon Chun, In Taek Hwang
  • Patent number: 9845493
    Abstract: The invention relates to cleavable chemistry in general, and in particular, to tunable fluorescence using cleavable linkers present in fluorochrome-quencher conjugates.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: December 19, 2017
    Assignee: Agency for Science, Technology and Research
    Inventors: Sydney Brenner, Yin Nah Teo, Pee Mei Tan
  • Patent number: 9845494
    Abstract: The invention relates to methods for enzymatic, genotyping of polymorphisms on solid supports. In some aspects the methods include ligation of allele or base specific interrogation probes to an array probe. The array probe is labeled by ligation of the interrogation probe. Ligation is dependent on the identity of the base immediately adjacent to the end of the array probe. In other aspects array bound probes are labeled by template dependent extension.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: December 19, 2017
    Assignee: Affymetrix, Inc.
    Inventors: Glenn K. Fu, Keith W. Jones
  • Patent number: 9845495
    Abstract: [Problem] To provide a method for detecting a nucleic acid (such as DNA and RNA) under isothermal conditions, in particular a method by which a short-chain nucleic acid can be directly detected. [Solution] A method for detecting a target nucleic acid in a sample of the present invention comprises: (a) a step of preparing a first oligonucleotide which comprises, in the direction from 5? to 3?, a first arbitrary sequence, an endonuclease recognition site that is used in a nicking reaction, and a sequence complementary to the target nucleic acid; (b) a step of carrying out a nucleic acid amplification reaction using the target nucleic acid contained in the sample as a primer in the presence of an endonuclease which recognizes the endonuclease recognition site that is used in a nicking reaction; and (c) a step of detecting an oligonucleotide which is obtained by the nucleic acid amplification reaction and comprises a sequence complementary to the first arbitrary sequence.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: December 19, 2017
    Assignees: Abbott Laboratories, Tokyo Institute of Technology
    Inventor: Ken Komiya
  • Patent number: 9845496
    Abstract: Digital assay system, including methods, apparatus, and compositions, for performing target assays in partitions each containing a generic reporter and a specific reporter for target amplification.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: December 19, 2017
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: John F. Regan, Svilen S. Tzonev, Yann Jouvenot, Claudia Litterst, Dianna Maar, Geoff McDermott
  • Patent number: 9845497
    Abstract: The invention provides methods, devices, compositions and kits for diagnosing or predicting transplant status or outcome in a subject who has received a transplant.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: December 19, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen R. Quake, Thomas M. Snyder, Hannah Valantine
  • Patent number: 9845498
    Abstract: A method of detecting an analyte is provided. The method includes providing a sample, a container 110 with a wall 115, and a catalyst for a luminescent reaction. The wall includes a colored portion 115b. The method further comprises forming a reaction in the container and detecting the presence or absence of light emitted from the reaction mixture in the container. Detecting light emitted from the container can comprise detecting light passing through the colored portion. The colored portion can be detected visually and the color can be associated with the identity of an analyte-specific reagent disposed in the container. Kits comprising the container and a catalyst for a luminescent reaction are also provided.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: December 19, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Neil Percy, Gregory W. Sitton
  • Patent number: 9845499
    Abstract: A microfluidic device can have a plurality of microchambers connected to a microchannel via siphon apertures. The microfluidic device may be formed from a thermoplastic and capped by a thermoplastic thin film. The microfluidic device may be used for digital polymerase chain reactions by forcing reagent into the microchambers at low pressure via an inlet, forcing any gas trapped in the microfluidic device to outgas through the thin film by applying high pressure to the microfluidic device via inlets and outlets of the microfluidic device, and applying air at low pressure to the inlets in order to digitize the chambers such that the reagent in each chamber is isolated from the reagent in other chambers by an air gap. After digitization, the device may be used to run a digital polymerase chain reaction process.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: December 19, 2017
    Assignee: COMBINATI INCORPORATED
    Inventors: Ju-Sung Hung, Andrew Zayac, Megan Dueck
  • Patent number: 9845500
    Abstract: Nucleotide triphosphate probes containing a molecular and/or atomic tag on a ? and/or ? phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: December 19, 2017
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Susan H. Hardin, Xiaolian Gao, James Briggs, Richard Willson, Shiao-Chun Tu
  • Patent number: 9845501
    Abstract: This invention relates to improved methods for sequencing and genotyping nucleic acid in a single molecule configuration. The method involves single molecule detection of fluorescent labeled PPi moieties released from NTPs as a polymerase extension product is created.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: December 19, 2017
    Assignee: Pacific of Biosciences of California, Inc.
    Inventor: John G. K. Williams
  • Patent number: 9845502
    Abstract: Compositions, methods and kits are disclosed for high-sensitivity single molecule digital counting by the stochastic labeling of a collection of identical molecules by attachment of a diverse set of labels. Each copy of a molecule randomly chooses from a non-depleting reservoir of diverse labels. Detection may be by a variety of methods including hybridization based or sequencing. Molecules that would otherwise be identical in information content can be labeled to create a separately detectable product that is unique or approximately unique in a collection. This stochastic transformation relaxes the problem of counting molecules from one of locating and identifying identical molecules to a series of binary digital questions detecting whether preprogrammed labels are present. The methods may be used, for example, to estimate the number of separate molecules of a given type or types within a sample.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 19, 2017
    Assignee: Cellular Research, Inc.
    Inventors: Stephen P. A. Fodor, Glenn K. Fu
  • Patent number: 9845503
    Abstract: A nucleic acid tag comprising a nucleotide-support platform attached to a nucleic acid molecule, an odorant, and an encapsulant. Unique nucleic acid-containing tags containing an odorant are seeded at one or more geographic locations. Using odorant-detection systems, the person or object of interest is examined for the presence of one or more of the odorant, thereby revealing the presence of the seeded nucleic acids and eliminating the expense and time associated with unnecessary screening. The geographic location associated with each detected nucleic acid is used to backtrack the item's path or extrapolate a probable point of origin.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: December 19, 2017
    Assignee: SRC, Inc.
    Inventor: Mary F. Swartz
  • Patent number: 9845504
    Abstract: An in vitro method for the prognosis or prediction of response in patients with rheumatoid arthritis to treatment with agents recognising the B-lymphocyte CD20 membrane receptor. The method of the invention comprises an assay in a blood sample from these patients and measuring, before starting the treatment, the transcriptional expression level (mRNA) of at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, LRRN3, HLA-DQA1, NLK, TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770, ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orf145 and SNTA1; and the comparison of this expression level to the expression values previously obtained in patients who responded and who did not respond to the treatment.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: December 19, 2017
    Assignee: Fundació Institut de Recerca de L'Hospital Universitari Vall D'Hebron
    Inventors: Antonio Juliá Cano, Sara Marsal Barril
  • Patent number: 9845505
    Abstract: Response to treatment of an inflammatory condition can be predicted based on characteristics of one or more markers from a subject. The markers can include expressions of nucleotide sequences identified herein and of combinations thereof. A response value can be calculated based on characteristics (e.g., expression levels) of one or more of the markers, as well as other characteristics of the subject, such as baseline clinical data. The treatment can be administered when the response value is beyond a threshold.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: December 19, 2017
    Assignee: BLUEPRINT BIO, INC.
    Inventors: Patrick Lilley, Matthew Nunez
  • Patent number: 9845506
    Abstract: A method for determining the prognosis of prostate cancer in a subject is provided which comprises the assessment of the methylation status of the HSPB1 gene in a prostate cancer sample.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: December 19, 2017
    Assignee: Queen Mary University of London
    Inventors: Attila Lorincz, Natasa Vasiljevic, Amar Ahmad